Alzheimer’s Disease Trial Designs Struggle To Turn Noise Into Sound
Infographic compares pivotal trials for Alzheimer's disease-modifying candidates from Biogen/Eisai, Lilly and Roche.
You may also be interested in...
Keeping Track: New Claims For Tukysa, Brukinsa; US FDA Wants More Patients To Support Donanemab, Pediatric Airsupra Bids
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Lilly CEO: Realistic Expectations Needed For Current Wave of Alzheimer’s Treatments
Successive waves of Alzhiemer’s therapies are going to be needed, David Ricks said as his company awaits Phase III data on donanemab, the last of three late-stage anti-amyloid drugs to report results.
US FDA Complete Response Letter Rates Vary With Sponsor Size
Pink Sheet infographic illustrates benefits of big pharma’s resources and experience.